Literature DB >> 8353286

Human endothelial cells express proteinase 3, the target antigen of anticytoplasmic antibodies in Wegener's granulomatosis.

W J Mayet1, E Csernok, C Szymkowiak, W L Gross, K H Meyer zum Büschenfelde.   

Abstract

Autoantibodies directed against cytoplasmic antigens of neutrophils (ANCA), especially proteinase 3 (PR-3), have proved to be a useful clinical tool confirming the diagnosis or monitoring disease activity of Wegener's granulomatosis (WG). Although several concepts concerning the pathophysiologic potentials of ANCA have been discussed, only sparse data about ANCA-endothelium interactions have been available. In this study, we have investigated the expression of PR-3 in cytokine-treated human endothelial cells using purified anti-PR-3 antibodies of patients with WG, murine and human monoclonal anti-PR-3 antibodies as probes. We were able to show that tumor necrosis factor-alpha, interleukin-1 alpha/beta, and interferon-gamma led to an increased PR-3 expression in the cytoplasm of endothelial cells by performing polymerase chain reaction analysis, Western blot, cyto-enzyme-linked immunosorbent assays, and confocal laser scanning microscopy. Moreover, PR-3 was also translocated into the cell membrane, becoming accessible to ANCA. Our data suggest a possible direct pathogenic effect of anti-PR-3 antibodies in WG and other vasculitides. Anti-PR-3 antibodies represent an important missing link in ANCA-endothelial interactions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8353286

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

Review 1.  Combination therapy in autoimmune disease: vasculitis.

Authors:  D Carruthers; P Bacon
Journal:  Springer Semin Immunopathol       Date:  2001

2.  Drug-induced neutropenia associated with anti-neutrophil cytoplasmic antibodies (ANCA): possible involvement of complement in granulocyte cytotoxicity.

Authors:  T Akamizu; S Ozaki; H Hiratani; H Uesugi; J Sobajima; Y Hataya; N Kanamoto; M Saijo; Y Hattori; K Moriyama; K Ohmori; K Nakao
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

Review 3.  Role of proteinase 3 in activation of endothelium.

Authors:  M E Taekema-Roelvink; C van Kooten; C A Verburgh; M R Daha
Journal:  Springer Semin Immunopathol       Date:  2001

4.  Cigarette smoking and risk of primary systemic vasculitis: a propensity score matching analysis.

Authors:  Alireza Khabbazi; Babak Alinejati; Mehrzad Hajialilo; Morteza Ghojazadeh; Aida Malek Mahdavi
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

Review 5.  ANCA--pathophysiology revisited.

Authors:  C G Kallenberg; E Brouwer; A H Mulder; C A Stegeman; J J Weening; J W Tervaert
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

Review 6.  Functional properties of antiendothelial cell antibodies.

Authors:  A Kollmeier; M Kreditor; J George; Y Levy; Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 7.  Antineutrophil cytoplasm antibodies and vasculitis.

Authors:  M C Nash; M J Dillon
Journal:  Arch Dis Child       Date:  1997-09       Impact factor: 3.791

8.  Anti-proteinase-3 (PR3) antibodies (C-ANCA) recognize various targets on the human umbilical vein endothelial cell (HUVEC) membrane.

Authors:  M De Bandt; O Meyer; L Dacosta; C Elbim; C Pasquier
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

9.  Binding of proteinase 3 and myeloperoxidase to endothelial cells: ANCA-mediated endothelial damage through ADCC?

Authors:  B E Ballieux; K T Zondervan; P Kievit; E C Hagen; L A van Es; F J van der Woude; M R Daha
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

10.  Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis: a predominant role for the IgG3 subclass of ANCA.

Authors:  A H Mulder; C A Stegeman; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.